同日宣布，林慧怡已获委任为联席公司秘书、授权代表及法律程序代理人，自2025年11月21日起生效。 林慧怡将与另一位现任联席公司秘书张俊环共同履行公司秘书职责。 格隆汇11月21日丨海西新药(02637.HK)宣布，陈晓琳已辞任(i)公司联席公司秘书；(ii)联交所证券上市规 则第3.05条项下所规定的公司授权代表("上市规则项下的授权代表")；(iii)根据香港法例第622章《公司 条例》第16部项下的公司授权代表(连同上市规则项下的授权代表称为"授权代表")；及(iv)上市规则第 19A.13(2)条所规定代公司在香港接收法律程序文件及通知书的公司授权人士("法律程序代理人")，自 2025年11月21日起生效。 ...

海西新药(02637)发布公告，陈晓琳女士已辞任(i)公司联席公司秘书;(ii)《香港联合交易所有限公司证券 上市规则》第3.05条项下所规定的公司授权代表;(iii)根据香港法例第622章《公司条例》第16部项下的 公司授权代表;及(iv)上市规则第19A.13(2)条所规定代公司在香港接收法律程序文件及通知书的公司授权 人士，自2025年11月21日起生效。 林慧怡女士已获委任为联席公司秘书、授权代表及法律程序代理人，自2025年11月21日起生效。 ...

智通财经APP讯，海西新药(02637)发布公告，陈晓琳女士已辞任(i)公司联席公司秘书;(ii) 《香港联合交 易所有限公司证券上市规则》第3.05条项下所规定的公司授权代表;(iii)根据香港法例第622章《公司条 例》第16部项下的公司授权代表;及 (iv)上市规则第19A.13(2)条所规定代公司在香港接收法律程序文件 及通知书的公司授权人士，自2025年11月21日起生效。 林慧怡女士已获委任为联席公司秘书、授权代表及法律程序代理人，自2025年11月21日起生效。 ...

（股份代號：2637） 聯席公司秘書、授權代表及法律程序代理人變更 與 豁免嚴格遵守上市規則第 3.28 條及第 8.17 條 聯席公司秘書、授權代表及法律程序代理人變更 福建海西新藥創制股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，陳曉 琳女士（「陳女士」）已辭任(i)本公司聯席公司秘書（「聯席公司秘書」）；(ii) 《香港聯合 交易所有限公司（「聯交所」）證券上市規則（「上市規則」）》第3.05條項下所規定的本 公司授權代表（「上市規則項下的授權代表」）；(iii)根據香港法例第622章《公司條例》 第16部項下的本公司授權代表（連同上市規則項下的授權代表稱為「授權代表」）；及 (iv)上市規則第19A.13(2)條所規定代本公司在香港接收法律程序文件及通知書的本 公司授權人士（「法律程序代理人」），自2025年11月21日起生效。 陳女士已確認，彼與董事會概無意見分歧，亦無與彼辭任有關的事宜需提請聯交所 及本公司股東垂注。 – 1 – 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內 ...

Core Viewpoint - HaiXi New Drug (02637.HK) experienced a significant increase in stock price, rising over 10% to reach a new high of 145.9 HKD, marking an approximate 70% increase from its IPO price of 86.4 HKD [2] Summary by Category - **Stock Performance** - The stock price of HaiXi New Drug reached 145.9 HKD, representing a rise of 10.87% at the time of reporting [2] - The trading volume was reported at 16.7142 million HKD [2] - **Market Reaction** - The stock has set a new record high since its listing, indicating strong market interest and investor confidence [2]

Group 1 - HaiXi Pharmaceutical (02637) saw its stock price rise over 10%, reaching a new high of HKD 145.9, which is nearly a 70% increase from its IPO price of HKD 86.4 [1] - As of the IPO disclosure date, HaiXi Pharmaceutical has 15 approved generic drug products, covering multiple therapeutic areas including digestive, cardiovascular, endocrine, and nervous systems [1] - The four core generic drugs, namely Anbili, Ruiantuo, Haihuitong, and Saixifu, are expected to contribute over 90% of the company's revenue, projected to reach CNY 425 million in 2024 [1] Group 2 - HaiXi Pharmaceutical is also developing an innovative drug pipeline, including C019199, an immunotherapy targeting CSF-1R/DDR1/VEGFR2, currently in I/II clinical stages for indications like osteosarcoma and tenosynovial giant cell tumor, with plans to start a Phase III trial in the second half of 2025 [1] - Another drug, HXP056, is an oral treatment for wet age-related macular degeneration, expected to complete its Phase I clinical trial by the end of 2025 [1]

Core Viewpoint - Haixi New Drug (02637) has seen a significant stock price increase, reaching a new high of 145.9 HKD, which is nearly 70% higher than its IPO price of 86.4 HKD [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company with 15 approved generic drug products covering various therapeutic areas, including digestive, cardiovascular, endocrine, and nervous systems [1] - Since 2021, four core generic drugs have been included in the national drug procurement program, contributing over 90% of the company's revenue, projected to reach 425 million CNY in 2024 [1] Research and Development Pipeline - The company is also developing innovative drugs, including C019199, an immunotherapy targeting CSF-1R/DDR1/VEGFR2, currently in I/II clinical stages for indications like osteosarcoma and tenosynovial giant cell tumor, with plans to start a Phase III trial in the second half of 2025 [1] - Another drug, HXP056, is an oral treatment for wet age-related macular degeneration, expected to complete its Phase I clinical trial by the end of 2025 [1]

Core Insights - As of November 10, a total of 108 stocks reached their 52-week highs, with notable performers including Taijin Holdings (08321), OKURA HOLDINGS (01655), and Hejia Holdings (00704) achieving high rates of 125.00%, 84.90%, and 53.57% respectively [1] Summary by Category 52-Week Highs - Taijin Holdings (08321) closed at 0.620 with a peak price of 0.900, marking a 125.00% increase - OKURA HOLDINGS (01655) reached a closing price of 0.280 and a high of 0.355, reflecting an 84.90% rise - Hejia Holdings (00704) had a closing price of 0.345 and a peak of 0.430, showing a 53.57% increase - Other notable stocks include Sanhe Chemical (00301) with a 41.67% increase and Aide New Energy (02623) with a 36.25% rise [1] 52-Week Lows - Wangshan Wangshui-B (02630) recorded a closing price of 52.850 and a low of 51.000, resulting in a -21.84% decrease - Eight Horses Tea (06980) had a closing price of 52.850 and a low of 51.100, reflecting a -10.98% decline - New Enjoy Times (08519) reached a low of 0.270, marking a -10.00% drop - Other significant declines include Jiujiang Bank (06190) at -8.99% and Kun Group (00924) at -6.98% [3][4]

Group 1: Hong Kong Stock Exchange Performance - Hong Kong Stock Exchange reported total revenue of HKD 21.851 billion for the first three quarters, a year-on-year increase of 37% [1] - Main business income reached HKD 20.438 billion, up 41% year-on-year, while net profit was HKD 13.419 billion, reflecting a 45% increase [1] - The exchange achieved record highs in revenue and profit for the third consecutive quarter, indicating strong market activity and operational efficiency [1] Group 2: Biopharmaceutical Company Performance - Biopharmaceutical company Wangshan Wangshui-B saw a significant increase of 154.72% in the dark market, closing at HKD 85 per share [2] - The company focuses on discovering, developing, and commercializing small molecule drugs in the fields of neuropsychiatry and reproductive health [2] - The surge in dark market trading highlights strong market interest in the biopharmaceutical sector, particularly in neuropsychiatry and reproductive health treatments [2] Group 3: Electric Vehicle Company IPO - Seres (09927.HK) became the largest IPO for a Chinese automotive company in Hong Kong, raising over HKD 14 billion [3] - The company attracted 22 cornerstone investors and issued 108.6 million shares at a price of HKD 131.5 each [3] - The successful listing reflects the strong momentum in China's electric vehicle industry and positive market expectations for high-growth companies [3] Group 4: Instant Noodle Company Stock Performance - Master Kong Holdings (00322.HK) saw its stock price rise over 4%, closing at HKD 11.86, marking a new high since July [4] - Goldman Sachs reported that the company's profit targets are likely to be met, driven by pricing strategies, cost advantages, efficiency improvements, and strict promotional management [4] - The strong stock performance indicates optimistic market sentiment regarding the company's profitability outlook [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 福建海西新藥創制股份有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02637 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 78,707,270 | RMB | | | 1 RMB | | 78,707,270 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 78,707,270 | RMB | | | 1 RMB | | 78,707,270 | 本月底法定/註冊股本總額： RMB ...